Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.66 |
| ▸ | ITGAV | P06756 | 20/20 | 0.66 |
| ▸ | ITGA2B | P08514 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7982746 | 0.96 | ITGB3 (0.65) | ITGB3ITGAVITGA2B | |
| SCHEMBL7396784 | 0.95 | ITGB3 (0.60) | ITGB3ITGAVITGA2B | |
| SCHEMBL7402818 | 0.91 | ITGB3 (0.59) | ITGB3ITGAVITGA2B | |
| SCHEMBL7402084 | 0.88 | ITGAV (0.67) | ITGB3ITGAVITGA2B | |
| SCHEMBL7402219 | 0.87 | ITGB3 (0.67) | ITGB3ITGAVITGA2B | |
| SCHEMBL7403933 | 0.87 | ITGB3 (0.70) | ITGB3ITGAVITGA2B | |
| SCHEMBL7405719 | 0.86 | ITGB3 (0.63) | ITGB3ITGAVITGA2B | |
| SCHEMBL7986014 | 0.85 | ITGB3 (0.67) | ITGB3ITGAVITGA2B | |
| SCHEMBL7404638 | 0.83 | ITGB3 (0.69) | ITGB3ITGAVITGA2B | |
| SCHEMBL7403338 | 0.83 | ITGB3 (0.62) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | claimed |
| US-6214834-B1 | ANGIOGENESIS INHIBITORS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS | DUPONT PHARMACEUTICALS COMPANY | 2001-04-10 | — | — | US | disclosed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |